Cargando…
Comment on ‘Costs of managing adverse events in the treatment of first-line metastatic renal cell carcinoma: bevacizumab in combination with interferon-α2a compared with sunitinib’
| Autores principales: | , |
|---|---|
| Formato: | Texto |
| Lenguaje: | English |
| Publicado: |
Nature Publishing Group
2010
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2967059/ https://www.ncbi.nlm.nih.gov/pubmed/20938457 http://dx.doi.org/10.1038/sj.bjc.6605886 |
| _version_ | 1782189636199645184 |
|---|---|
| author | Charbonneau, C Sandin, R |
| author_facet | Charbonneau, C Sandin, R |
| author_sort | Charbonneau, C |
| collection | PubMed |
| description | |
| format | Text |
| id | pubmed-2967059 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2010 |
| publisher | Nature Publishing Group |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-29670592010-11-15 Comment on ‘Costs of managing adverse events in the treatment of first-line metastatic renal cell carcinoma: bevacizumab in combination with interferon-α2a compared with sunitinib’ Charbonneau, C Sandin, R Br J Cancer Letter to the Editor Nature Publishing Group 2010-10-12 2010-09-14 /pmc/articles/PMC2967059/ /pubmed/20938457 http://dx.doi.org/10.1038/sj.bjc.6605886 Text en Copyright © 2010 Cancer Research UK https://creativecommons.org/licenses/by-nc-sa/3.0/This work is licensed under the Creative Commons Attribution-NonCommercial-Share Alike 3.0 Unported License. To view a copy of this license, visit http://creativecommons.org/licenses/by-nc-sa/3.0/ |
| spellingShingle | Letter to the Editor Charbonneau, C Sandin, R Comment on ‘Costs of managing adverse events in the treatment of first-line metastatic renal cell carcinoma: bevacizumab in combination with interferon-α2a compared with sunitinib’ |
| title | Comment on ‘Costs of managing adverse events in the treatment of first-line metastatic renal cell carcinoma: bevacizumab in combination with interferon-α2a compared with sunitinib’ |
| title_full | Comment on ‘Costs of managing adverse events in the treatment of first-line metastatic renal cell carcinoma: bevacizumab in combination with interferon-α2a compared with sunitinib’ |
| title_fullStr | Comment on ‘Costs of managing adverse events in the treatment of first-line metastatic renal cell carcinoma: bevacizumab in combination with interferon-α2a compared with sunitinib’ |
| title_full_unstemmed | Comment on ‘Costs of managing adverse events in the treatment of first-line metastatic renal cell carcinoma: bevacizumab in combination with interferon-α2a compared with sunitinib’ |
| title_short | Comment on ‘Costs of managing adverse events in the treatment of first-line metastatic renal cell carcinoma: bevacizumab in combination with interferon-α2a compared with sunitinib’ |
| title_sort | comment on ‘costs of managing adverse events in the treatment of first-line metastatic renal cell carcinoma: bevacizumab in combination with interferon-α2a compared with sunitinib’ |
| topic | Letter to the Editor |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2967059/ https://www.ncbi.nlm.nih.gov/pubmed/20938457 http://dx.doi.org/10.1038/sj.bjc.6605886 |
| work_keys_str_mv | AT charbonneauc commentoncostsofmanagingadverseeventsinthetreatmentoffirstlinemetastaticrenalcellcarcinomabevacizumabincombinationwithinterferona2acomparedwithsunitinib AT sandinr commentoncostsofmanagingadverseeventsinthetreatmentoffirstlinemetastaticrenalcellcarcinomabevacizumabincombinationwithinterferona2acomparedwithsunitinib |